CHRISTIE BALLANTYNE to Research Design
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Research Design.
Connection Strength
0.139
-
Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009 Dec; 158(6):896-901.e3.
Score: 0.058
-
The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. Control Clin Trials. 1996 Dec; 17(6):550-83.
Score: 0.023
-
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. Clin Cardiol. 2016 Mar; 39(3):137-44.
Score: 0.022
-
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014 Apr; 15(4):380-8.
Score: 0.019
-
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects?on low-density lipoprotein-cholesterol reduction. J Clin Lipidol. 2012 Mar-Apr; 6(2):180-91.
Score: 0.017